domains with the binding site for LFA-1 localized to specific residues in the first N-terminal domain (14) . Most LFA 1-dependent phenomena could be inhibited by blocking mAb to ICAM-1 (10, 15, 16) . However, binding of lymphocytes to cultured human umbilical vein endothelial cells (HUVEC) showed that the ICAM-1 blocking mAb, RRl/1, could not inhibit all the LFA1-dependent adhesion (15). This implied a second ligand for LFA-1 existed on endothelial cells . Similarly, LFA-1 mAb but not ICAM-1 mAb blocked PMAinduced aggregation of a T cell lymphoblastoid cell line, SKW3 (10) . Lastly, LFAI-dependent cytolysis ofcertain target cells by T cells was not inhibitable with mAb to ICAM-1 (16), further evidence for additional LFA-1 ligands. A cDNA clone for a second LFA-1 ligand, termed ICAM-2, was obtained by transfecting COS cells with an endothelial cDNA library and selecting for binding to LFA-1 coated plates in the presence ofblocking ICAM-1 mAb (17) . Like ICAM-1, ICAM-2 is a member of the immunoglobulin superfamily. It has only two immunoglobulin-like domains that are most homologous to the two N-terminal domains ofICAM-1, with 35% amino acid identity (17) .
In this study we report on the biochemical and cellular nature of ICAM-2 using mAb generated to COS cells transiently expressing the ICAM-2 cDNA. Two murine mAb to ICAM-2, CBR-IC2/1 and CBRIC2/2, were generated . Using these antibodies, the cellular and tissue distribution, biochemical properties and functional role in cell-cell adhesion of ICAM-2 could be studied. ICAM-2 was found to differ from ICAM-1 in both its distribution and inducibility, implying a functional difference between the two molecules . Several LFA-1-dependent, ICAM-1-independent cell interactions could be accounted for by ICAM-2, whereas others revealed the presence of a third, as yet undefined, ligand for LFA-1 .
Materials and Methods
Monoclonal Antibodies. The following previously described murine mAbs to human antigens were used: TS2/9 (anti-LFA-3, IgGl) (18) , TS2/16 (anti-CD29, IgGl) (18) , TSl/22 (anti-CDlla, IgGl) (18) , RR1/1 (anti-ICAM-1, IgGl) (10), W6/32 (anti-HLAA,B,C, IgG2a) (19) , and X63 (nonbinding antibody, IgGl) .
Cell Culture. The murine myeloma P3X63Ag8 .653 (20) was maintained in DMEM supplemented with 10% Fetal Bovine Serum (FBS), 5 mM glutamine and 50 kg/ml gentamyein (supplemented DMEM) at 37°C in a humidified 10% COZ atmosphere. Hybridomas were initially grown in supplemented DMEM under HAT selection (100 FM hypoxanthine, 400 nM aminopterin, 16 /AM thymidine), transferred to supplemented DMEM under HT selection (100/AM hypoxanthine and 16 AM thymidine) and later grown solely in supplemented 10% FBS/DMEM. The human fibrosarcoma cell line, FS 1,2,3 and epitheloid carcinoma cell line, HeLa, were grown in 10% FBS/DMEM plus supplements at 37°C and 10% C02 . All other human cell lines were grown in RPMI 1640 medium supplemented with 10% FBS, 5 mM glutamine and 50 Fcg/ml gentamycin at 37°C and 5% C02 . All cell lines used in this study are listed in Table 2 .
Human umbilical vein endothelial cells (HUVEC, passage number 2-4) were maintained as a monolayer on fibronectin-coated dishes in M199 medium, 20% PBS (Hyclone Laboratories, Inc ., Logan, UT; LPS = 0.025 ng/ml), 5 mM glutamine, 50 14g/ml gentamycin, 100 Pg/ml endothelial growth supplement (Biomedical Technologies, Inc., Stoughton, MA) and 100 jig/ml heparin at 37°C and 5% CO2 . For stimulation, 5 U/ml of recombinant human IIr1s (Boehringer Mannheim, Indianapolis, IN), 10,ag/ml of LPS (Sigma Chemical Co., St. Louis, MO), 20 ng/ml ofrecombinant human TNF-a (Genzyme, Boston, MA) or 103 U/ml of recombinant IFN-y (Genzyme) was added to the medium at either 4 or 24 h before harvesting. Stimulation of HUVEC was monitored by flow cytometry analysis of ICAM-1 on treated and untreated cells.
Peripheral blood mononuclear cells (PBMC) were obtained by dextran sedimentation and Ficoll-Hypaque (1.077) centrifugation as described (15). Granulocytes were recovered from the cell pellet; contaminating erythrocytes were removed by hypotonic lysis. Lymphocytes were enriched by incubating the PBMC in 10% FBS/RPMI 1640 on tissue culture-treated plastic Petri dishes for 2 h and saving the nonadherent cells. To enrich for T lymphocytes, the nonadherent cells were passed through nylon wool (21) . NK cells were further isolated from plastic and nylon wool nonadherent mononuclear cells by Percoll (Pharmacia Fine Chemicals, Piscataway, NJ) gradient centrifugation as described (22) . CD3' cells were removed by labelling with CD3 mAb (OKT3) and removing the mAb bound cells by rosetting with magnetic beads (Dynal; Bobbins Scientific, Mountain View, CA) coated with F(ab') 2 goat anti-mouse IgG and IgM (Tago Inc., Burlingame, CA). Immunofluorescence flow cytometry showed the purified NK cells to be >75% CD16' with few (<10%) contaminating CD3' cells. PHA blasts were prepared from isolated PBMC, incubated in supplemented RPMI, plus 10% FBS and 10 Fig/ml PHA-P (Sigma Chemical Co.) and assayed at the indicated times (23) . Plastic adherent monocytes were either analyzed immediately or cultured in vitro for 10 d to induce differentiation towards macrophage-like cells (24) . The adherent cells were removed with HBSS/EDTA and surface antigen expression examined by immunofluorescence flow cytometry.
cDNA and Transfection . ICAM-1 and ICAM-2 cDNAs in the transient expression vector CDM8 (13, 17) or vector alone (mock) were transfected into COS cells using DEAE-dextran (25) . 3 d after transfection, cells were detached with 10 mM HBSS/EDTA, washed three times in 10%FBS/RPMI 1640 and then used for immunization, flow cytometric analysis, "5 I-labeling, or binding to LFA-1-coated plates . Cells were washed twice with PBS, pH 7.3, before either immunization or ... I-labeling .
Development ofICAM-2 Hybridomas. Transfected COS cells expressing ICAM-2 were used to immunize 3-12-wk-old BALB/c female mice (Charles River Laboratories, Wilmington, MA) . Immunizations (105-106 cells/i.p. immunization) were performed four times at 3-wk intervals . 3 d before fusion with the murine myeloma P3X63Ag8.653, the mice were injected both i.p. and i.v. with 5 x 105 COS cells transiently expressing ICAM-2 . These transfectants were tested for ICAM-2 expression by specific binding to LFA-1 . The protocol for fusion and subsequent maintenance of hybridomas is as previously described (26) . Differential reactivity to ICAM-2 transfected COS cells and untransfected cells was used initially to screen for ICAM-2 mAbs. Initial screening was performed by ELISA, followed by flow cytometric analysis of putative ICAM-2 reactive hybridoma supernatants. Positive mAbs were then screened for reactivity to cell lines known to be either positive (SKW3) or negative (HeLa) for ICAM-2 by Northern blotting analysis (17) . MAbs selected for further analysis were cloned twice by limiting dilution and isotyped by ELISA using affinity purified antibodies to mouse immunoglobulins (Zymed Immunochemicals, San Francisco, CA). 254
Characterization of ICAM-2 and Evidence for a Third Counter-Receptor
Immunohistochemical Staining. Fresh tissues were received at the Department of Surgical Pathology at Thomas Jefferson University and snap-frozen in liquid nitrogen . The tissues were stored at -70°C until use. Immunohistological staining was carried out following the alkaline phosphatase (AP) anti-alkaline phosphatase procedure (27) . Briefly, 7 jLm frozen tissue sections were air-dried overnight and fixed in acetone for 10 min. ICAM-1 (RR1/1) and ICAM-2 (CBRIC2/1) mAb were applied at 1/12,000 and 1/2,000 dilutions of ascites fluid, respectively, for 30 min followed by brief washing in Tris-buffered saline, pH 7.6 . As a negative control, mouse serum at a 1/5,000 dilution was applied. After washing, the sections were incubated with a 1/40 dilution of rabbit anti-mouse Ig mAb (Dakopatts, Carpinteria, CA) for 30 min. Finally, after intermittent washing, the cells were incubated with APAAPcomplex (anti-AP mouse mAb preincubated with AP). The last two steps were repeated in order to enhance the sensitivity of this procedure. Bound alkaline phosphatase was visualized using new fuchsin (Sigma Chemical Co .) as substrate. Levamisole was applied in order to block endogenous alkaline phosphatase activity and Meyer's acid hematoxylin (Sigma Chemical Co.) was used as counterstain .
Flow Cytometric Analysis . Adherent cells were removed with 10 mM HBSS/EDTA, washed with PBS/2% FBS and 50 Al of a 0.5-1.0 x 106 cells/ml suspension was added to either 50 ul of mAb supernatant or 50 P1 of a 1/200 dilution of mAb containing ascites fluid. After 45 min incubation at 4°C, the cells were washed and incubated with 100 P1 of a 1/20 dilution of FITC-labeled goat anti-mouse Ig (Zymed Immunochemicals) for 45 min at 4°C. The cells were rewashed and fixed in 1% paraformaldehyde/PBS . Samples were analyzed using an Epics V (Coulter Diagnostics, Hialeah, FL) flow cytometer. As both primary and secondary mAb were used at saturating concentrations, membrane antigen expression could be quantitated as a measure of mean fluorescence intensity using EPICS Immuno-Brite fluorescent beads (Coulter Diagnostics) to calibrate the cytometer, and X63 control antibody staining used to subtract nonspecific fluorescence .
Surface Iodination . Surface labeling of cells with 1a'I was performed as described using Iodogen (Pierce Chemical Co., Rockford, IL) (28) . Cells were labeled with 1251 (1 .0 mCi Na 1251; Amersham Corp ., Arlington Heights, IL) and lysed for 45 min at 4°C in 1 ml of lysis buffer (10 mM Tris HCl pH 8.0, 150 mM NaCl, 1% Triton-X-100, 1% hemoglobin, 1 mM iodoacetamide, 1 mM PMSF, 0.24 TIU/ml aprotonin, 0.025% azide) . Nuclei and insoluble debris were removed by centrifugation at 14,000 g for 20 min and lysates precleared overnight at 4'C with 100 Al of packed bovine IgG coupled-Sepharose. The lysate was then incubated with 30 P1 packed mAb bound to Sepharose for 2 h. The beads were washed four times in 25 mM Tris HCl pH 8.0,150 mM NaCl, 0.1% Triton-X-100, twice in 25 mM Tris pH 8 .0, 150 mM NaCl, and once in 50 mM Tris pH 8.0. The beads were then treated with an equal volume of 2 x SDS-PAGE sample buffer, boiled for 2 min and analyzed on 8% vertical slab polyacrylamide gels as previously described (29) . Proteins were visualized by autoradiography. Treatment of samples with N-glycanase (Genzyme Corp.) was as previously described (33) , using a concentration (3 U/ml) determined to give optimal cleavage of all N-linked oligosaccharides from the peptide backbone .
Purification of LFA-1 . LFA1 was purified from JY lysates on TS2/4-Sepharose as described previously (30) . The LFA-1 bound to TS2/4-Sepharose was eluted with 50 mM triethylamine pH 11 .5, 150 mM NaCl, 2 mM MgCl2, and 1% octyl (3-D-glucopyranoside (OG). Samples were neutralized and stored frozen at -70°C. 25 5 de Fougerolles et al . (31) or endothelial cell monolayers (15) hasbeen described previously. Briefly, confluent endothelial cell monolayers in 96-well plates were treated with a 1/200 dilution of the appropriate ascites for 45 min at 37'C and then unbound mAb was removed by washing before the binding assay. MAb pretreatment of cells consisted of incubation with a 1/200 dilution of ascites for 45 min at 4°C, after which 0.75-1.0 x 105 cells were transferred to each well . Cells were allowed to settle and adhere to either the solid phase LFA1 or the endothelial monolayers for 1 h at 37°C . Washing consisted of 6 aspirations with either a 21-gauge needle (monolayers) or a 25-gauge needle (LFA-1-coated plates). Wells were examined microscopically before and after washing to assess the evenness of cell settling and damage to the endothelial monolayer. Damage to the monolayer was never significant (<5% area). Fluorescence was directly quantitated from the 96-well plates using a Pandex fluorescence concentration analyzer (Baxter Healthcare Corp., Mundelein, IL).
Adherence of ICAM-2' COS cell transfectants to LFA-1-coated wells was performed as previously described (31) . In short, 5 x 10^Na2 51 CrOo-labeled transfectants were bound to LFA-1-coated plates for 1 h at room temperature, and washed with four aspirations through a 26-gauge needle. Bound cells were eluted and quantitated by -y counting.
Aggregation Assay. A qualitative aggregation assay was carried out as described (32) . Briefly, 50 pl of a cell suspension (2 x 106/ml) in 10% FBS/RPMI 1640 was preincubated with a 1/100 dilution of ascites (1/200 final concentration) for 45 min at 4°C. These cells were then stimulated with 50 ng/mL of PMA and added to a flat bottom 96-well microtiter plate (Becton Dickinson, Lincoln Park, NJ) . Cells were incubated for 2-6 h at 37°C, viewed with an inverted microscope and aggregation scored visually. Because these two cell lines aggregate with different kinetics, the length of the assay was varied to maximize PMAinduced aggregation UY: 2 h; SKW3 : 5 h) . Scores ranged from 0 to 5, where 0 indicates essentially no cells were clustered; 1 indicates less than 10% of cells were in clusters; 2 indicates between 10-50% of cells were in aggregates ; 3 indicates 50-100% of cells were in aggregates ; 4 indicates nearly 100% of cells were in large clusters of aggregates; and 5 indicates that all the cells were in very compact aggregates . Photomicrographs of aggregating cells were taken using a Nikon DiaphotTMD inverted microscope (Nippon Kogaku, Tokyo, Japan) and phase contrast optics .
Results

CONTROL ANTI-ICAM-1 ANTI-ICAM-2
Development of Anti-ICAM-2 MAbs. Hybridomas producing anti-ICAM-2 mAb were generated by the fusion of myeloma cells with spleen cells from mice immunized with COS cells transfected with ICAM-2 cDNA . Two mAb, CBR-IC2/1(IgG2a) and CBR IC2/2 (Ig02a) were produced which bound specifically to COS cells transfected with ICAM-2 cDNA but not to COS cells transfected with ICAM-1 cDNA
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Characterization of ICAM-2 and Evidence for a Third Counter-Receptor Fig . 3 ). Normal fetal (21 wk) and adult tissues showed a pattern of ICAM-1 staining similar to that previously reported (34, 35) . In contrast to ICAM-1, the distribution of ICAM-2 was restricted to the endothelium and some lymphoid cells. ICAM-2 was expressed on all blood vessel endothelium, including high endothelial venules (Fig. 3 D) , and expression was consistently stronger than that seen for ICAM-1 . Examination of germinal centers of lymphoid tissue revealed ICAM-2 to be absent on most cells (Fig. 3 B and D) . In the spleen, although ICAM-2 was virtually absent on all lymphocytes in the white pulp, strong reactivity was seen on the sinus lining cells of the red pulp (Fig. 3 B) . In addition to the marginal reactivity of follicular mantle cells, ICAM-2 was found to be strongly expressed on small clusters of lymphocytes within germinal centers of both spleen and tonsil (Fig. 3 D) . As expected, anti-ICAM-1 mAb showed intense reactivity with the germinal centers oflymphoid follicles, most likely representing reactivity with B cells and follicular dendritic cells, while the follicular mantle and marginal zones of the follicle showed weaker reactivity ( Fig. 3 A and C) . ICAM-1 was highly expressed on tonsil surface and crypt epithelium (Fig. 3 C) , Organs studied : lymph node, tonsil, spleen, thymus, heart, brain, peripheral nerve tissue, skin, lungs, stomach, small and large intestine, liver, kidney, ovary, uterus, mammary gland, adrenal gland, and thyroid gland. Strong expression is denoted as "+" and lack of expression is denoted as " -"; "( + )" indicates a partial reactivity. Where not indicated, tissues were negative for both ICAM-1 and ICAM-2 . t Marginal reactivity for ICAM-2 was observed for follicular mantle cells in the spleen . 5 Small foci of germinal center lymphocytes were positive for ICAM-2 . Peyer's patches + Lymphocytes of the mucosal stroma + whereas ICAM-2 was not . Fetal thymus expressed high levels of ICAM-1 in the medulla and only low levels in the cortex, while ICAM-2 reactivity was confined to vessel endothelium. In the cortical region ICAM-1 expression was primarily focal on dendritic and epithelial cells, whereas high levels ofICAM-1 in the medulla was localized to both the dendritic/macrophage cells and the thymocytes. In nonlymphoid organs, several differences in expression were observed between ICAM-1 and ICAM-2 (Table 1) . While macrophages, fibroblast-like cells, and dendritic cells expressed high levels of ICAM-1 in most tissues studied, ICAM-2 expression in tissues was restricted to blood vessel endothelium . Additional ICAM-2 expression was seen only in the liver and the kidney. In the liver, ICAM-2 was weakly expressed on Kupffer cells and some sinusoidal lining cells (Fig. 3 F) . ICAM-1 by comparison was strongly expressed by Kupffer cells and sinusoidal lining cells (Fig. 3 E) . In kidney, the glomerular capillary endothelium expressed ICAM-2, as did the intertubular spindle cells (Fig, 3 M. The ICAM-2 expression in kidney, although weaker than ICAM-1, was similar in its distribution (Fig. 3 G) . These exceptions aside, ICAM-2 was not present on any other tissues studied, including small and large intestine, striated and smooth muscle, brain, thyroid gland, and skin.
Immunofuorescence Flow Cytometry of ICAM-2 Membrane Expression. Flow cytometric analysis of human tumor cell lines and PBLs supported the results obtained in frozen tissue sections (Table 2) . Resting lymphocytes and purified T cells expressed both ICAM-1 and ICAM-2 at low levels, although ICAM-2 was always significantly higher in expression than ICAM-1 . The pattern of expression for ICAM-2 differed from ICAM-1 in that nearly all resting cells were ICAM-2 positive and expression increased only slightly upon PHA activation. Two-color flow cytometry revealed resting T (CD3+) and B (CD20+) lymphocytes to express equivalent amounts of ICAM-2 on their cell surface (data not shown) . In contrast to resting lymphocytes, freshly purified monocytes showed greater ICAM expression, with ICAM-1 and ICAM-2 being generally equivalent . In vitro culturing of monocytes has been used as a method of obtaining macrophage-like CD16 + cells (24) . Upon culturing of monocytes to induce macrophage differentiation, ICAM-2 expression remained unchanged, whereas the inducibility of ICAM-1 was consistent with published data (34) .
Expression of ICAM-2 on cell lines was coordinate with Northern blotting analysis. Lines which had been previously shown to express ICAM-2 mRNA (HUVEC, SKW3, Jurkat, BBN, Ramos, U937) or lack ICAM-2 mRNA (HeLa, FS1,2,3) showed corresponding patterns of cell surface expression ( Table  2 ). All T and B lymphoblastoid lines examined expressed considerable ICAM-2, while other cell lines exhibited a broad range of expression. Treatment ofseveral cell lines (HUVEC, JY, and SKW3) with phosphoinositol-phospholipase C (PI-PLC), revealed no PI-linked form of ICAM-2 as cell surface expression remained unchanged (data not shown). Mouse lymphoblastoid and fibroblastic cell lines did not react with the anti-human ICAM-2 mAb, implying that these mAb did . not crossreact to murine ICAM-2 .
ICAM-2 Expression on Cultured Endothelial Cells. Of all cell types examined, ICAM-2 was most highly expressed on endothelial cells . We examined the relative levels of ICAM expression on resting and stimulated human umbilical vein endothelial cells (Fig. 4) . Resting endothelial cells showed low basal level expression of ICAM-1 and approximately 10-fold higher ICAM-2 expression. The level of ICAM-2 expression was also significantly higher than that seen for either LFA-3 or HLAA, B, C. Upon stimulation ofendothelial cells with TNF-ce, ICAM-1 expression increased after 4 h, becoming maximal after 24 h stimulation, while ICAM-2 expression remained unchanged. LFA3 was largely unaffected by cytokine stimulation, whereas HLAA,B,C showed slightly increased expression, as previously reported (15, 36, 37). Identical findings were obtained with a variety of other stimuli including Ilrl0, LPS, and IFN--y (data not shown) . ICAM-2 therefore was found to be constitutively expressed at high levels on HUVEC and, unlike ICAM-1, was not increased by stimulation with inflammatory mediators .
Functional Characterization ofICAM-2 MAh To determine whether CBR-IC2/1 and CBR/IC2/2 could inhibit ICAM-2-LFA-1 interaction, binding of ICAM-2+ COS cells to purified LFA-1 was performed in the presence ofthese mAb (Fig. 5) . A high percentage of transfected cells bound to purified LFA-1 in the presence of control mAb W6/32, and this was totally inhibitable by an anti-LFA-1 mAb . Of the tion, whereas CBR-IC2/2 completely blocked adherence to levels seen in the presence of anti-LFA 1 mAb. A combination of both anti-ICAM-2 mAb gave no additional inhibition to that seen when using CBRIC2/2 alone. Both mAb were used at saturating concentrations, and this inhibitory effect could be diluted out . Similar results were obtained using mouse L cells stably expressing human ICAM-2, demonstrating the ability of mAb CBR IC2/2 to completely inhibit ICAM-2 interaction was purified LFA 1(data not shown). CBR-IC2/1 and CBRAC2/2 were determined to recognize nearby but distinct epitopes on ICAM-2, because although CBR IC2/2 would completely block CBR-IC2/1 binding, the latter could only partially block the former (data not shown) . Effect ofAnti-ICAM-2 MAbs on Homotypic Aggregation. We examined the ability of anti-ICAM-1 and anti-ICAM-2 mAb to inhibit LFA1-dependent homotypic aggregation of several cell lines (Table 3 and Fig. 6 ). PMAinduced aggregation ofJY, an EBVtransformed B lymphoblastoid cell line, was previously found to be inhibitable almost completely by the blocking anti-ICAM-1 mAb, RR1/1 (10). Alone, anti-ICAM-1 mAb was found to inhibit most aggregation (Fig.  6 C) , but when used in conjunction with anti-ICAM-2 mAb aggregation was inhibited completely ( Fig. 6 E) ; to the same extent as with anti-LFA-1 mAb (Fig. 6 F) . Consistent with the functional characterization of both CBRIC2/1 and CBR-IC2/2, when the anti-ICAM-2 mAb were used separately with RR1/1, only CBRIC2/2 inhibited aggregation . Aggregation was not inhibited by the anti-ICAM-2 mAb alone ( Fig. 6 D) ; this is due to the presence of ICAM-1 and the overriding role it plays in LFA1-dependent aggregate formation of this cell line. PMA treatment of cells resulted in little change in surface expression ofeither ICAM-1, ICAM-2, or LFA-1 during the course of the assay (data not shown) . After 12-24 h however, ICAM-1 expression increased and ICAM-2 showed a slight decrease .
PMAinduced aggregation ofSKW3 was shown to be LFA 1-dependent, but ICAM-1-independent (Table 3) . This is consistent with previously published reports (10) . Anti-ICAM-2 mAb had no effect on SKW3 aggregation either alone or in combination with RR1/1 ( Table 3) «ICAM-1 + 2 «HLA cell lines to purified LFA-1 was performed (Fig. 7) . Consistent binding of all cell lines to purified LFA1 was observed in the presence of control X63 mAb. Similar binding was achieved if no mAb was added or ifother control mAbs were used (W6/32, TS2/9, TS2/16 ; data not shown) . Paralleling the aggregation results, JY binding to purified LFA1 was largely inhibitable with anti-ICAM-1 mAb alone, and when combined with anti-ICAM-2 mAb, binding was further inhibitable to the level seen in the presence ofanti-LFA 1 mAb.
Little inhibition was seen when anti-ICAM-2 mAb were used alone. SKW3 binding to LFA1 was only slightly inhibited with a combination ofmAb to ICAM-1 and ICAM-2, whereas binding was abolished with LFA-1 mAb. This third mechanism of adhesion to LFA1 was also present at suboptimal LFA1 sites densities and was resistant to stringent washing conditions (21-gauge needle aspiration) (data not shown) .
Numerous other cell lines were tested and several Ourkat, Sup T, Ramos, Molt 4) also expressed an ICAM-1, ICAM-2-independent pathway of adhesion to LFA1(data not shown) .
Binding of unstimulated HUVEC to purified LFA1 was found to be entirely ICAM-1 and ICAM-2-dependent . MAb to either ICAM-1 or ICAM-2 had little effect alone, whereas the combination of mAb to ICAM-1 and ICAM-2 eliminated binding as effectively as LFA1 mAb. B Lymphoblastoid Cell Adhesion to HUVEC. The adhesion of the JY B lymphoblastoid cell line to HUVEC is an ideal in vitro system in which to study LFA1-dependent binding of lymphocytes to endothelial cells (Fig. 8) . Several mechanisms of lymphocyte-endothelial adhesion exist, of which LFA-1-ICAM and VLA4VCAM-1 are the most important and intensively studied (1, 38, 39) . Since JY cells lack 01 expression (A. de Fougerolles and T.A . Springer, unpublished observations), adhesion of these cells to endothelium allows the LFA-1-ICAM interactions to be studied independently (15) of any /31-dependent interactions, such as VLA-4VCAM-1 . The contribution of CD2-LFA-3 interactions to initial lymphocyte-endothelial cell adhesion has previously been shown to be minimal (15), and this is reflected in the inability of LFA-3 mAb to inhibit JY binding to HUVEC (Fig . 8) . Previously, it was shown that binding of JY cells to HUVEC occurred via two LFA-1-dependent pathways, an inducible ICAM-1-dependent pathway and an uninducible ICAM-1-independent pathway (15). To examine if this ICAM-1-independent pathway of adhesion was due to ICAM-2, JY adhesion to HUVEC was assayed in the presence of ICAM-2 Discussion ICAM-2 was initially described and characterized as a cDNA clone that encoded a counter receptor for LFA-1 (17) . In this study we have reported the production of two murine mAb to ICAM-2 which allow the characterization of the ICAM-2 molecule. ICAM-2 was found to be a broad band by SDS-PAGE o£ Mr 55-65,000 under reducing conditions. Unlike ICAM-1 (34), little variation in size was seen for ICAM-2 immunoprecipitated from different cell lines . Based on cDNA sequence, ICAM-2 has a polypeptide backbone of M r 28,393 and six potential Winked glycosylation sites (17) . Glycosylation of ICAM-2 accounted for an increase in M, of 30,000-35,000, about 5,000 M r /N-linked site. Comparatively, ICAM-1 has 8 Winked glycosylation sites, which account for about 41,000 M r of the apparent Mr in SDS-PAGE . An increase of about 3,000 Mr /N-linked glycosyla- 263 de Fougerolles et al. The distributions of ICAM-1 and ICAM-2 on cell lines parallel closely the immunohistology results . Expression of ICAM-2 was most pronounced on HUVECs, where its level on resting endothelial cells was consistently 10-15-fold higher than that for ICAM-1. ICAM-2 expression on resting lymphocytes was several-fold higher than that seen with ICAM-1, while monocytes expressed equivalent levels of ICAM-1 and ICAM-2 . ICAM-1 is strongly expressed on melanoma and carcinoma cells (41, 42) , whereas ICAM-2 is not . The weak expression of ICAM-2 observed on leukocytes by immunofluorescence flow cytometry was undetectable by immunohistochemical analysis of tissue sections, presumably due to the lower sensitivity of this technique.
The inducibility of ICAM-1 and constitutive expression of ICAM-2 have important implications for their role in inflammatory and immune responses . Previous studies have shown that although ICAM-1 was expressed at very low basal levels on endothelial cells, it was readily inducible by exposure of HUVEC to recombinant IMot, IIrl,3, IFN-.
y, TNF-a, and LPS (15, 36, 37) . A second noninducible ligand on endothelial cells for LFA-1 was described (15) and was postulated to be ICAM-2 (17) . Indeed, our studies on ICAM-2 confirmed these predictions. ICAM-2 surface expression on endothelial cells is unaffected by a variety of inflammatory cytokines. Similarly, while ICAM-1 was upregulated upon stimulation ofresting lymphocytes, ICAM-2 expression was unchanged . These results point towards ICAM-1 being the major ligand for LFA-1 during inflammatory or immune responses, while ICAM-2 is of more relative importance in the unstimulated resting state or early on during a response before ICAM-1 expression is increased.
ICAM-2 is the predominant LFA1 ligand on resting endothelium, and therefore this pathway of adhesion between lymphocytes and resting endothelium may have important consequences for normal recirculation of lymphocytes through tissue endothelium . The importance of LFA-1 in recirculation is demonstrated by the 40 to 60% reduction in normal lymphocyte migration into lymph nodes and Peyer's patches that is seen following in vivo treatment with LFA1 mAb (43) . Naive and memory T cells show distinct pathways of recirculation, as memory T cells selectively exit from blood through peripheral tissue endothelium, whereas naive T cells exit through lymph node high endothelial venules (44) . ICAM-2 is an attractive candidate ligand to facilitate memory T cell recirculation as it is basally expressed at high levels on resting endothelium and memory T cells have increased LFA-1 expression (45) . Similarly, resting T lymphocytes express little or no ICAM-1, and as such ICAM-2 may be important in initial T cell adhesion with antigen presenting cells that bear LFA-1 (46, 47) . Indeed, in both allogeneic and autologous mixed lymphocyte reaction a role is suggested for LFA-1 ligand(s) other than ICAM-1 (48) . Another immune reaction where cell-to-cell contact is required is direct cytotoxicity. Lysis of certain targets by T cells appear to occur in an ICAM-1-independent, LFA-1-dependent manner (16). It will be of interest to see what role ICAM-2 plays in these phenomena .
A mAb that blocks binding ofICAM-2 to LFA-1 was used to investigate several phenomena that were known to be LFA1-dependent, yet ICAM-1-independent (10, 15) . One such case involves homotypic aggregation of JY, an EBV transformed B lymphoblastoid cell line. PMA-induced aggregation of this cell line, while completely LFA-1-dependent, was only partially inhibitable with mAb to ICAM-1 (10). Our results confirm these findings and extend them to show that ICAM-2 accounts for the remaining aggregates. While the ICAM-2 mAb in combination with ICAM-1 mAb can inhibit all aggregation, the ICAM-2 mAb alone has no inhibitory effect on aggregation . This observation highlights one important difference between ICAM-1 and ICAM-2, namely their relative avidity for LFA 1. By immunofluorescence ICAM-1 and ICAM-2 are expressed at similar levels on JY, yet by far the major adhesive component in homotypic aggregation and binding to purified LFA-1 is due to ICAM-1. Similar findings are seen with HUVEC binding to LFA1 and JY adhesion to HUVEC, where although resting endothelial cells express 10-fold more ICAM-2 than ICAM-1, the effect of the anti-ICAM-2 mAb is roughly equivalent to that seen with the anti-ICAM-1 mAb. Even after 4 h TNF-a stimulation of endothelial cells, when ICAM-2 surface expression is still several-fold greater than ICAM-1, JY binding to HUVEC is largely inhibitable by ICAM-1 mAb (data not shown). Lastly, when comparing adhesion to purified LFA-1 of transfected COS cells expressing equivalent levels of ICAM-1 and ICAM-2, the ICAM-1 expressing cells were more resistant to increased washing shear force than were the ICAM-2 expressing COS cells (17) . All of these experiments point towards ICAM-2 being the lower affinity ligand for LFA-1. At the present time the exact reason for the lower affinity of LFA1 for ICAM-2, as compared to ICAM-1, is not known, although differences in LFA-1 binding sites, and decreased accessibility ofLFA1 for ICAM-2, due to its shorter two domain structure and increased level of glycosylation, are all plausible explanations.
Another important distinction between ICAM-1 and ICAM-2 is the spectrum of integrins with which they interact. Although ICAM-1 has been shown to interact with another leukocyte integrin, Mac-1 (49), ICAM-2 shows no detectable binding to Mac-1. Presently, LFA-1 is the only known counter-receptor for ICAM-2 .
Aside from purely adhesive interactions, there may well be qualitative differences in how ICAM-1 and ICAM-2 interact with LFA-1. Previously, it had been shown that resting T cells could be actived through combination of immobilized anti-CD3 antibodies and purified ICAM-1 (50, 51) . It will thus be interesting to see if ICAM-2 can exert similar effects, and ascertain if signal transduction via LFA-1 is the same when using ICAM-2 as ligand . Similarly, activation of T cells through CD3 causes a change in LFA-1 avidity from low to high, resulting in increased binding ofT cells to purified ICAM-1 (30) . By examining if this avidity change also extends to ICAM-2 binding, it would be possible to further dissect differences between the ICAMs. Another area where ICAM-1 and ICAM-2 could potentially differ is in their association with cytoplasmic proteins . Preferential interaction with either ICAM-1 or ICAM-2, perhaps dictated in focal adhesions by the contact distance between cells, could then result in different cytoskeletal changes affecting the overall structure and organization of the cell.
Certain LFA-1-dependent ICAM-1-independent phenomena were found not to be accountable for by ICAM-2, thus suggesting the possibility of additional LFA1 ligand(s). A third ligand was found to be largely responsible for SKW3 PMA-induced homotypic aggregation, and several cell lines, including SKW3, were found to bind to LFA1-coated plastic in an ICAM-1, ICAM-2-independent manner. The strength
